D
Daniel Habermehl
Researcher at Technische Universität München
Publications - 110
Citations - 3018
Daniel Habermehl is an academic researcher from Technische Universität München. The author has contributed to research in topics: Radiation therapy & Carbon Ion Radiotherapy. The author has an hindex of 33, co-authored 107 publications receiving 2546 citations. Previous affiliations of Daniel Habermehl include University Hospital Heidelberg & Ludwig Maximilian University of Munich.
Papers
More filters
Journal ArticleDOI
Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy.
Sebastian Adeberg,Christian Hartmann,Thomas Welzel,Stefan Rieken,Daniel Habermehl,Andreas von Deimling,Jürgen Debus,Stephanie E. Combs +7 more
TL;DR: RT should be offered after surgical resection after initial diagnosis to increase progression-free survival as well as overall survival, and outcome is comparable to other series reported in the literature.
Journal ArticleDOI
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
N. Andratschke,H. Alheid,Michael Allgäuer,Gerhild Becker,Oliver Blanck,Judit Boda-Heggemann,Thomas B. Brunner,Marciana-Nona Duma,Sabine Gerum,Matthias Guckenberger,Guido Hildebrandt,Rainer J. Klement,V. Lewitzki,C. Ostheimer,Alexandros Papachristofilou,Cordula Petersen,Thomas Schneider,Robert Semrau,Stefan Wachter,Daniel Habermehl +19 more
TL;DR: After an initial learning curve with regards to total cumulative doses, consistently high biologically effective doses have been employed translating into high local tumor control at 1 and 2 years and overall survival is mainly influenced by histology and metastatic tumor burden.
Journal ArticleDOI
Skull base meningiomas: Long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT)
Stephanie E. Combs,Sebastian Adeberg,Jan Oliver Dittmar,Thomas Welzel,Stefan Rieken,Daniel Habermehl,Peter E. Huber,Jürgen Debus +7 more
TL;DR: Precision photon radiotherapy leads to long-term tumor control with minimal side effects, but also with preservation of QOL in patients with skull base meningiomas.
Journal ArticleDOI
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Daniel Habermehl,Kerstin A. Kessel,Thomas Welzel,Holger Hof,Amir Abdollahi,Frank Bergmann,Stefan Rieken,Jürgen Weitz,Jens Werner,Peter Schirmacher,Markus W. Büchler,Jürgen Debus,Stephanie E. Combs +12 more
TL;DR: A high percentage of patients with locally advanced pancreatic cancer can undergo secondary resection after gemcitabine-based chemoradiation and has a relative long-term prognosis after complete resection.
Journal ArticleDOI
Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients
Stephanie E. Combs,Malte Ellerbrock,Thomas Haberer,Daniel Habermehl,Angelika Hoess,Oliver Jäkel,Alexandra D Jensen,Swantje Klemm,Marc W. Münter,Jakob Naumann,Anna Nikoghosyan,Susanne Oertel,Katia Parodi,Stefan Rieken,Jürgen Debus +14 more
TL;DR: The first 80 patients treated with proton and carbon ion radiotherapy and described patient selection, treatment planning and daily treatment for different indications suggest particle therapy could be included successfully into the clinical routine at the Department of Radiation Oncology in Heidelberg.